Takeda doubles U.K. rep ranks to boost oncology, IBD sales

Carly Helfand Takeda has its eye on some serious growth–and to help it get there, it's bringing its U.K. sales force in-house. Beginning this June, 70 contract staffers–including ...

Shkreli, Valeant CEO set for a grilling at congressional price-hike hearing

Emily Wasserman Vocal pricing critic Rep. Elijah Cummings (D-MD) has his chance to put some pharma execs in the hot seat. Former Turing Pharmaceuticals CEO Martin Shkreli, who kicked ...

Crossovers fund a $61M round for Twist Bio, spotlighting possible IPO

John Carroll Just 7 months after coming up with a $ 37 million Series C, Twist Bioscience has gone back to the well and drawn up another $ 61 million in private investor cash. That ...

French drug trial disaster leaves patient dead amid a slew of unanswered questions

Damian Garde The patient left brain-dead in last week's botched drug trial has died, French authorities said, spurring more questions about how a routine Phase I study went awry ...

Top 10 mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accent

John Carroll FierceBiotech News

Acorda bags PhIII Parkinson’s drug in $363M Biotie buyout

John Carroll FierceBiotech News

Syros raises $40M to get its leukemia drug into Phase II

Damian Garde Syros Pharmaceuticals raised $ 40 million in equity to push forward with its pipeline of genetically targeted drugs, securing the cash it needs to take its top prospect ...

Amgen hits a snag in its plot to challenge AbbVie’s blockbuster Humira

Damian Garde Amgen, at work on a biosimilar of AbbVie's best-selling treatment, got an unfavorable decision from U.S. regulators that could delay the launch of its take on Humira. FierceBiotech ...

Don’t split up the dynamic duo of GSK’s vaccines and drugs, vax chief says

Carly Helfand Prominent U.K. investor Neil Woodford has been calling for a four-way breakup of GlaxoSmithKline, a company he says is too "complicated" for its own good. But ...

NIH urged to ‘break taboo’ against using its power to bypass drug patents

Emily Wasserman The National Institutes of Health (NIH) has said that it would take "extraordinary" circumstances for the agency to address rising drug prices, even as skyrocketing ...

Gene therapy player Spark eyes a groundbreaking approval by 2017

Damian Garde Spark Therapeutics, at work on gene therapies for rare diseases, laid out an ambitious three-year plan that would see its top candidate win FDA approval and 9 others enter ...

GSK chief Witty opens up to spinoff talk, with consumer health an obvious choice

Tracy Staton GlaxoSmithKline CEO Andrew Witty may be coming around on a breakup. At the J.P. Morgan Healthcare Conference, Witty said he's open to the idea and pegged his consumer ...
Page 2 of 3212345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS